Maria Greenwald

9.6k total citations · 3 hit papers
76 papers, 5.1k citations indexed

About

Maria Greenwald is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Maria Greenwald has authored 76 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Rheumatology, 21 papers in Genetics and 17 papers in Hematology. Recurrent topics in Maria Greenwald's work include Rheumatoid Arthritis Research and Therapies (41 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Autoimmune and Inflammatory Disorders Research (14 papers). Maria Greenwald is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (41 papers), Chronic Lymphocytic Leukemia Research (21 papers) and Autoimmune and Inflammatory Disorders Research (14 papers). Maria Greenwald collaborates with scholars based in United States, Belgium and United Kingdom. Maria Greenwald's co-authors include Mark C. Genovese, Stanley Cohen, Paul Emery, Edward Keystone, Maxime Dougados, E. Hessey, Richard Furie, Mark C. Totoritis, Gerd‐Rüdiger Burmester and Matthew Cravets and has published in prestigious journals such as New England Journal of Medicine, The American Journal of Cardiology and Journal of the American Geriatrics Society.

In The Last Decade

Maria Greenwald

72 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks

2006 1.3k citations Stanley Cohen, Paul Emery et al. profile →
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

2016 301 citations Maxime Dougados, Désirée van der Heijde et al. Annals of the Rheumatic Diseases profile →
A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis

2023 74 citations Jay Tuttle, Edit Drescher et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Maria Greenwald

Since Specialization

Citations

This map shows the geographic impact of Maria Greenwald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Greenwald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Greenwald more than expected).

Fields of papers citing papers by Maria Greenwald

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Greenwald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Greenwald. The network helps show where Maria Greenwald may publish in the future.

Co-authorship network of co-authors of Maria Greenwald

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Greenwald. A scholar is included among the top collaborators of Maria Greenwald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Greenwald. Maria Greenwald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study 2025 ·RMD Open ·René Westhovens, Kevin Winthrop, Arthur Kavanaugh, Maria Greenwald, Lorenzo Dagna, Regina Cseuz, R. Besuyen, (unknown), (unknown), (unknown), Mark C. Genovese, Paul Emery, Patrick Verschueren, Rieke Alten	2
2	Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk‐Enriched Rheumatoid Arthritis Patients 2024 ·Arthritis & Rheumatology ·Christina Charles‐Schoeman, Roy Fleischmann, Eduardo Mysler, Maria Greenwald, Steven R. Ytterberg, Gary G. Koch, Deepak L. Bhatt, Cunshan Wang, Ted R. Mikuls, (unknown), Carol A. Connell, John Woolcott, Sujatha Menon, Yan Chen, Kristen Lee, Zoltán Szekanecz	13
3	POS0307 A PHASE 2 TRIAL OF PERESOLIMAB FOR ADULTS WITH RHEUMATOID ARTHRITIS 2023 ·Annals of the Rheumatic Diseases ·Jay Tuttle, Edit Drescher, Jesus Abraham Simón Campos, Paul Emery, Maria Greenwald, A. Kivitz, (unknown), Pia P. Yachi, (unknown), Ajay Nirula	1
4	Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs 2018 ·RMD Open ·Désirée van der Heijde, Maxime Dougados, Ying‐Chou Chen, Maria Greenwald, Edit Drescher, (unknown), Li Xie, Inmaculada de la Torre, Terence Rooney, (unknown), Douglas Schlichting, Stephanie de Bono, Paul Emery	17
5	Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis 2018 ·Rheumatology and Therapy ·Alvin F. Wells, Maria Greenwald, John Bradley, Jahangir Alam, Vineet M. Arora, (unknown)	4
6	BARICITINIB INHIBITS RADIOGRAPHIC PROGRESSION OF STRUCTURAL JOINT DAMAGE AT 1 YEAR IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) AND AN INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CSDMARDS) 2017 ·Internal Medicine Journal ·Mark C. Genovese, Désirée van der Heijde, Maxime Dougados, (unknown), Maria Greenwald, Edit Drescher, (unknown), (unknown), Inmaculada de la Torre, Terence Rooney, Sarah Witt, D. Schlichting, Stephanie de Bono, Paul Emery	1
7	Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study breakdown → 2016 ·Annals of the Rheumatic Diseases ·Maxime Dougados, Désirée van der Heijde, Ying‐Chou Chen, Maria Greenwald, Edit Drescher, Jiajun Liu, Scott D. Beattie, Sarah Witt, Inmaculada de la Torre, C. Gaich, Terence Rooney, Douglas Schlichting, Stephanie de Bono, Paul Emery	301
8	Baricitinib, an Oral Janus Kinase (JAK) 1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to cDMARD Therapy: Results of the Phase 3 RA-BUILD Study 2016 ·The Journal of Rheumatology ·Maxime Dougados, D. van der Heijde, (unknown), Maria Greenwald, Edit Drescher, (unknown), Scott D. Beattie, Inmaculada de la Torre, Terence Rooney, D. Schlichting, Stephanie de Bono, (unknown), Arthur Bookman	2
9	Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2) 2016 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh, Joel M. Kremer, (unknown), Regina Cseuz, O. V. Reshetko, Mykola Stanislavchuk, Maria Greenwald, Annegret Van der Aa, Frédéric Vanhoutte, Chantal Tasset, Pille Harrison	176
10	Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib 2015 ·BMC Musculoskeletal Disorders ·Tore K Kvien, Maria Greenwald, Paul M. Peloso, Hongwei Wang, Anish Mehta, Arnold R. Gammaitoni	10
11	Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis 2014 ·New England Journal of Medicine ·Philip J. Mease, Mark C. Genovese, Maria Greenwald, Christopher T. Ritchlin, André Beaulieu, Atul Deodhar, Richard Newmark, (unknown), Ngozi Erondu, Ajay Nirula	308
12	Further assessment of the clinically effective dose range of etoricoxib: a randomized, double-blinded, placebo-controlled trial in rheumatoid arthritis 2011 ·Current Medical Research and Opinion ·Maria Greenwald, Paul M. Peloso, David R. Mandel, (unknown), Anish Mehta, (unknown), Judith A. Boice, Xiaojiang Zhan, Sean Curtis	6
13	Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study 2005 ·Annals of the Rheumatic Diseases ·Reginster Jy, S. Adámi, Péter L. Lakatos, Maria Greenwald, J Štěpán, Stuart L. Silverman, C. Christiansen, Lucy Rowell, Nicole Mairon, Bernard Bonvoisin, Marc K. Drezner, Ronald Emkey, Dieter Felsenberg, Cyrus Cooper, Pierre D. Delmas, Paul D. Miller	234
14	Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE 2005 ·Open Repository and Bibliography (University of Liège) ·Stuart Silverman, Maria Greenwald, Gillian Hawker, Claire Hughes, Nicole Mairon, Bernard Bonvoisin, Jean‐Yves Reginster	1
15	Efficacy and Safety of Rofecoxib 12.5 mg Versus Nabumetone 1,000 mg in Patients with Osteoarthritis of the Knee: A Randomized Controlled Trial 2004 ·Journal of the American Geriatrics Society ·Alan Kivitz, Maria Greenwald, Stanley Cohen, Adam B. Polis, (unknown), Mary Dixon, (unknown), (unknown), Herbert S. B. Baraf, Richard A. Petruschke, Alan K. Matsumoto, Gregory P. Geba, (unknown), (unknown)	27
16	Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women 2003 ·Osteoporosis International ·Robert S. Weinstein, A. M. Parfitt, Robert Marcus, Maria Greenwald, Gerald Crans, Douglas B. Muchmore	57
17	Effect of risedronate on the risk of hip fracture in elderly women. 2001 ·Ghent University Academic Bibliography (Ghent University) ·(unknown), P. Geusens, (unknown), H Zippel, Bensen Wg, C. Roux, S. Adámi, I. Fogelman, Terrence Diamond, Richard Eastell, P. J. Meunier, (unknown), Maria Greenwald, JM Kaufman, (unknown), Jean‐Yves Reginster	11
18	Rapid and consistent effect of risedronate on vertebral fracture risk reduction in elderly postmenopausal women 2000 ·Open Repository and Bibliography (University of Liège) ·Maria Greenwald, Manfréd M. Fischer, Jeffrey E. Poiley, (unknown), Jean‐Yves Reginster	1
19	Effect of bone density information on decisions about hormone replacement therapy: A randomized trial 1997 ·Obstetrics and Gynecology ·Stuart L. Silverman, Maria Greenwald, Ronald Klein, Barbara L. Drinkwater	56
20	Corticosteroid-induced osteoporosis: Effects of a treatment with slow-release sodium fluoride 1992 ·Osteoporosis International ·Maria Greenwald, (unknown), Stephen A. Spector, Stuart L. Silverman, (unknown)	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact